Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2011, Article ID 724871, 11 pages
http://dx.doi.org/10.1155/2011/724871
Review Article

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?

Multiple Sclerosis Clinic and Neuro-Immunology Laboratory, Department of Medicine, University of British Columbia, Room S-159, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2H5

Received 23 November 2010; Accepted 27 February 2011

Academic Editor: Mark S. Freedman

Copyright © 2011 Mona Alkhawajah and Joel Oger. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Rarlihof, M. Filippi, M. A. Horsfield et al., “Towards specific magnetic resonance imaging criteria in the early diagnosis of multiple sclerosis,” Neurology, vol. 45, supplement 4, p. A338, 1995. View at Google Scholar
  2. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar
  3. A. Traboulsee, “MRI relapses have significant pathologic and clinical implications in multiple sclerosis,” Journal of the Neurological Sciences, vol. 256, supplement 1, pp. S19–S22, 2007. View at Publisher · View at Google Scholar
  4. B. G. Weinshenker, B. Bass, G. P. A. Rice et al., “The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability,” Brain, vol. 112, no. 1, pp. 133–146, 1989. View at Google Scholar · View at Scopus
  5. D. S. Goodin and D. Bates, “Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode,” Multiple Sclerosis, vol. 15, no. 10, pp. 1175–1182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. L. Sayao, V. Devonshire, and H. Tremlett, “Longitudinal follow-up of "benign" multiple sclerosis at 20 years,” Neurology, vol. 68, no. 7, pp. 496–500, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Scalfari, A. Neuhaus, A. Degenhardt et al., “The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability,” Brain, vol. 133, no. 7, pp. 1914–1929, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Leray, J. Yaouanq, E. Le Page et al., “Evidence for a two-stage disability progression in multiple sclerosis,” Brain, vol. 133, no. 7, pp. 1900–1913, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Confavreux, S. Vukusic, and P. Adeleine, “Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process,” Brain, vol. 126, no. 4, pp. 770–782, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Debouverie, S. Pittion-Vouyovitch, S. Louis, and F. Guillemin, “Natural history of multiple sclerosis in a population-based cohort,” European Journal of Neurology, vol. 15, no. 9, pp. 916–921, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. B. Glad, H. Nyland, J. H. Aarseth, T. Riise, and K.-M. Myhr, “How long can you keep working with benign multiple sclerosis?” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 1, pp. 78–82, 2011. View at Publisher · View at Google Scholar
  12. M. Rovaris, F. Barkhof, M. Calabrese et al., “MRI features of benign multiple sclerosis toward a new definition of this disease phenotype,” Neurology, vol. 72, no. 19, pp. 1693–1701, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Rovaris, G. Riccitelli, E. Judica et al., “Cognitive impairment and structural brain damage in benign multiple sclerosis,” Neurology, vol. 71, no. 19, pp. 1521–1526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Chaudhuri, “Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis,” Medical Hypotheses, vol. 64, no. 3, pp. 608–618, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Tintoré, A. Rovira, J. Río et al., “Baseline MRI predicts future attacks and disability in clinically isolated syndromes,” Neurology, vol. 67, no. 6, pp. 968–972, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. P. Morrissey, D. H. Miller, B. E. Kendall et al., “The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study,” Brain, vol. 116, no. 1, pp. 135–146, 1993. View at Google Scholar · View at Scopus
  17. G. S. Gronseth and E. J. Ashman, “Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 54, no. 9, pp. 1720–1725, 2000. View at Google Scholar · View at Scopus
  18. L. Feuillet, F. Reuter, B. Audoin et al., “Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis,” Multiple Sclerosis, vol. 13, no. 1, pp. 124–127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. B. I. Glanz, C. M. Holland, S. A. Gauthier et al., “Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis,” Multiple Sclerosis, vol. 13, no. 8, pp. 1004–1010, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Potagas, E. Giogkaraki, G. Koutsis et al., “Cognitive impairment in different MS subtypes and clinically isolated syndromes,” Journal of the Neurological Sciences, vol. 267, no. 1-2, pp. 100–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. G. V. McDonnell, J. Cabrera-Gomez, D. B. Calne, D. K. B. Li, and J. Oger, “Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years,” Multiple Sclerosis, vol. 9, no. 2, pp. 204–209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. A. W. Varga, G. Johnson, J. S. Babb, J. Herbert, R. I. Grossman, and M. Inglese, “White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis,” Journal of the Neurological Sciences, vol. 282, no. 1-2, pp. 28–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. R. G. Henry, M. Shieh, D. T. Okuda, A. Evangelista, M. L. Gorno-Tempini, and D. Pelletier, “Regional grey matter atrophy in clinically isolated syndromes at presentation,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 11, pp. 1236–1244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Calabrese and P. Gallo, “Magnetic resonance evidence of cortical onset of multiple sclerosis,” Multiple Sclerosis, vol. 15, no. 8, pp. 933–941, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Rovaris, A. Gambini, A. Gallo et al., “Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution,” Neurology, vol. 65, no. 10, pp. 1626–1630, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. G. Henry, M. Shieh, B. Amirbekian, S. Chung, D. T. Okuda, and D. Pelletier, “Connecting white matter injury and thalamic atrophy in clinically isolated syndromes,” Journal of the Neurological Sciences, vol. 282, no. 1-2, pp. 61–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. Ranjeva, J. Pelletier, S. Confort-Gouny et al., “MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis,” Multiple Sclerosis, vol. 9, no. 6, pp. 554–565, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Calabrese, M. Atzori, V. Bernardi et al., “Cortical atrophy is relevant in multiple sclerosis at clinical onset,” Journal of Neurology, vol. 254, no. 9, pp. 1212–1220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. S. Yu, F. C. Lin, Y. Liu, Y. Duan, H. Lei, and K. C. Li, “Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis,” European Journal of Radiology, vol. 68, no. 2, pp. 328–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. G. Henry, M. Shieh, D. T. Okuda, A. Evangelista, M. L. Gorno-Tempini, and D. Pelletier, “Regional grey matter atrophy in clinically isolated syndromes at presentation,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 11, pp. 1236–1244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Audoin, W. Zaaraoui, F. Reuter et al., “Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 6, pp. 690–695, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. G. R. W. Moore, C. Laule, A. MacKay et al., “Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss,” Journal of Neurology, vol. 255, no. 11, pp. 1802–1811, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Flachenecker and P. Rieckmann, “Early intervention in multiple sclerosis: better outcomes for patients and society?” Drugs, vol. 63, no. 15, pp. 1525–1533, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. G. P. Rice, B. Incorvaia, L. Munari et al., “Interferon in relapsing-remitting multiple sclerosis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD002002, 2001. View at Google Scholar · View at Scopus
  35. G. Filippini, L. Munari, B. Incorvaia et al., “Interferons in relapsing remitting multiple sclerosis: a systematic review,” The Lancet, vol. 361, no. 9357, pp. 545–552, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. L. La Mantia, L. M. Munari, and R. Lovati, “Glatiramer acetate for multiple sclerosis,” Cochrane Database of Systematic Reviews, vol. 5, Article ID CD004678, 2010. View at Google Scholar · View at Scopus
  37. E. M. Frohman, E. Havrdova, F. Lublin et al., “Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis,” Archives of Neurology, vol. 63, no. 4, pp. 614–619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Oger, G. Francis, and P. Chang, “Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study,” Journal of the Neurological Sciences, vol. 237, no. 1-2, pp. 45–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. N. J. Carter and G. M. Keating, “Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis,” Drugs, vol. 70, no. 12, pp. 1545–1577, 2010. View at Publisher · View at Google Scholar
  40. P. Duquette, M. Girard, L. Despault et al., “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial,” Neurology, vol. 43, no. 4, pp. 655–661, 1993. View at Google Scholar
  41. L. D. Jacobs, D. L. Cookfair, R. A. Rudick et al., “Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis,” Annals of Neurology, vol. 39, no. 3, pp. 285–294, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. G. C. Ebers, G. Rice, J. Lesaux et al., “Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis,” The Lancet, vol. 352, no. 9139, pp. 1498–1504, 1998. View at Publisher · View at Google Scholar
  43. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995. View at Google Scholar · View at Scopus
  44. G. Comi, M. Filippi, and J. S. Wolinsky, “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis,” Annals of Neurology, vol. 49, no. 3, pp. 290–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Filippini, L. Munari, B. Incorvaia et al., “Interferons in relapsing remitting multiple sclerosis: a systematic review,” The Lancet, vol. 361, no. 9357, pp. 545–552, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Noseworth, D. Miller, and A. Compston, Disease-Modifying Treatments in Multiple Sclerosis, McAlpine's Multiple Sclerosis, 4th edition, 2006.
  47. M. Trojano, F. Pellegrini, A. Fuiani et al., “New natural history of interferon-β-treated relapsing multiple sclerosis,” Annals of Neurology, vol. 61, no. 4, pp. 300–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Ford, A. D. Goodman, K. Johnson et al., “Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate,” Multiple Sclerosis, vol. 16, no. 3, pp. 342–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Miller, V. Spada, D. Beerkircher, and R. R. Kreitman, “Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 4, pp. 494–499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. M. G. Brown, S. Kirby, C. Skedgel et al., “How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?” Neurology, vol. 69, no. 15, pp. 1498–1507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Hardmeier, S. Wagenpfeil, P. Freitag et al., “Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a,” Neurology, vol. 64, no. 2, pp. 236–240, 2005. View at Google Scholar
  52. F. Bagnato, S. Gupta, N. D. Richert et al., “Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations,” Archives of Neurology, vol. 62, no. 11, pp. 1684–1688, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. J. S. Wolinsky, P. A. Narayana, K. P. Johnson et al., “United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates,” Multiple Sclerosis, vol. 7, no. 1, pp. 33–41, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Paolillo, C. Pozzilli, E. Giugni et al., “A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta,” European Journal of Neurology, vol. 9, no. 6, pp. 645–655, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Fisher, R. A. Rudick, J. H. Simon et al., “Eight-year follow-up study of brain atrophy in patients with MS,” Neurology, vol. 59, no. 9, pp. 1412–1420, 2002. View at Google Scholar · View at Scopus
  56. R. Zivadinov, L. Locatelli, D. Cookfair et al., “Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy,” Multiple Sclerosis, vol. 13, no. 4, pp. 490–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. R. A. Rudick, J. C. Lee, K. Nakamura, and E. Fisher, “Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS,” Journal of the Neurological Sciences, vol. 282, no. 1-2, pp. 106–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. U. Bonati, L. K. Fisniku, D. R. Altmann et al., “Cervical cord and brain grey matter atrophy independently associate with long-term MS disability,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 82, no. 4, pp. 471–472, 2011. View at Google Scholar
  59. M. P. Sormani, L. Bonzano, L. Roccatagliata, G. L. Mancardi, A. Uccelli, and P. Bruzzi, “Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach,” Neurology, vol. 75, no. 4, pp. 302–309, 2010. View at Publisher · View at Google Scholar
  60. R. A. Rudick, J.-C. Lee, G. R. Cutter et al., “Disability progression in a clinical trial of relapsing-remitting multiple sclerosis eight-year follow-up,” Archives of Neurology, vol. 67, no. 11, pp. 1329–1335, 2010. View at Publisher · View at Google Scholar
  61. N. H. Pliskin, D. P. Hamer, D. S. Goldstein et al., “Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon β-1b,” Neurology, vol. 47, no. 6, pp. 1463–1468, 1996. View at Google Scholar · View at Scopus
  62. X. Montalban and J. Rio, “Interferons and cognition,” Journal of the Neurological Sciences, vol. 245, no. 1-2, pp. 137–140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. S. H. Pierson and N. Griffith, “Treatment of cognitive impairment in multiple sclerosis,” Behavioural Neurology, vol. 17, no. 1, pp. 53–67, 2006. View at Google Scholar · View at Scopus
  64. F. Patti, M. Amato, S. Bastianello et al., “Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis,” Multiple Sclerosis, vol. 16, no. 1, pp. 68–77, 2010. View at Publisher · View at Google Scholar
  65. S. Flechter, J. Vardi, Y. Finkelstein, and L. Pollak, “Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study,” Israel Medical Association Journal, vol. 9, no. 6, pp. 457–459, 2007. View at Google Scholar · View at Scopus
  66. A. Weinstein, S. I.L. Schwid, R. B. Schiffer, M. P. McDermott, D. W. Giang, and A. D. Goodman, “Neuropsychologic status in multiple sclerosis after treatment with glatiramer,” Archives of Neurology, vol. 56, no. 3, pp. 319–324, 1999. View at Google Scholar
  67. R. Bakshi, R. S. Miletich, K. Henschel et al., “Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients,” Neurology, vol. 53, no. 5, pp. 1151–1153, 1999. View at Google Scholar · View at Scopus
  68. S. P. van der Werf, P. J. H. Jongen, G. J. Lycklama À Nijeholt, F. Barkhof, O. R. Hommes, and G. Bleijenberg, “Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability,” Journal of the Neurological Sciences, vol. 160, no. 2, pp. 164–170, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. A. K. Andreasen, J. Jakobsen, L. Soerensen et al., “Regional brain atrophy in primary fatigued patients with multiple sclerosis,” NeuroImage, vol. 50, no. 2, pp. 608–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Pellicano, A. Gallo, X. Li et al., “Relationship of cortical atrophy to fatigue in patients with multiple sclerosis,” Archives of Neurology, vol. 67, no. 4, pp. 447–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Tedeschi, D. Dinacci, L. Lavorgna et al., “Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability,” Journal of the Neurological Sciences, vol. 263, no. 1-2, pp. 15–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. R. A. Marrie, E. Fisher, D. M. Miller, J. C. Lee, and R. A. Rudick, “Association of fatigue and brain atrophy in multiple sclerosis,” Journal of the Neurological Sciences, vol. 228, no. 2, pp. 161–166, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Ziemssen, J. Hoffman, R. Apfel, and S. Kern, “Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis,” Health and Quality of Life Outcomes, vol. 6, article 67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Putzki, Z. Katsarava, S. Vago, H. C. Diener, and V. Limmroth, “Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients,” European Neurology, vol. 59, no. 3-4, pp. 136–142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Orlewska, P. Mierzejewski, J. Zaborski et al., “A prospective study of the financial costs of multiple sclerosis at different stages of the disease,” European Journal of Neurology, vol. 12, no. 1, pp. 31–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. G. P. Rice, J. Oger, P. Duquette et al., “Treatment with interferon beta-1b improves quality of life in multiple sclerosis,” Canadian Journal of Neurological Sciences, vol. 26, no. 4, pp. 276–282, 1999. View at Google Scholar · View at Scopus
  77. D. Parkin, A. Jacoby, P. McNamee, P. Miller, S. Thomas, and D. Bates, “Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 2, pp. 144–149, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. C. J. Phillips, “The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment,” CNS Drugs, vol. 18, no. 9, pp. 561–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Iskedjian, J. H. Walker, T. Gray, C. Vicente, T. R. Einarson, and A. Gehshan, “Economic evaluation of Avonex (interferon beta-la) in patients following a single demyelinating event,” Multiple Sclerosis, vol. 11, no. 5, pp. 542–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Lazzaro, C. Bianchi, L. Peracino, P. Zacchetti, and A. Uccelli, “Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b,” Neurological Sciences, vol. 30, no. 1, pp. 21–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Detournay, “The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis,” Value in Health, vol. 5, no. 1, pp. 1–2, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. A. T. Reder, G. C. Ebers, A. Traboulsee et al., “Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS,” Neurology, vol. 74, no. 23, pp. 1877–1885, 2010. View at Publisher · View at Google Scholar
  83. R. M. Herndon, R. A. Rudick, F. E. Munschauer III et al., “Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis,” Multiple Sclerosis, vol. 11, no. 4, pp. 409–419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Weber-Schoendorfer and C. Schaefer, “Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study,” Multiple Sclerosis, vol. 15, no. 9, pp. 1037–1042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. H. J. Salminen, H. Leggett, and M. Boggild, “Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes,” Journal of Neurology, vol. 257, no. 12, pp. 2020–2023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Pakdaman, M. A. Sahraian, A. Fallah et al., “Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event,” Acta Neurologica Scandinavica, vol. 115, no. 6, pp. 429–431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Hughes and G. Francis, “PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS,” Neurology, vol. 56, no. 12, pp. 1628–1636, 2001. View at Google Scholar
  88. L. Kappos, A. Traboulsee, C. Constantinescu et al., “Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS,” Neurology, vol. 67, no. 6, pp. 944–953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. B. Greenberg, B. Khatri, and J. Kramer, “Current and emerging multiple sclerosis therapeutics,” Continuum: Lifelong Learning in Neurology, vol. 16, no. 5, pp. 58–77, 2010. View at Google Scholar
  90. O. Garcea, A. Villa, F. Cáceres et al., “Early treatment of multiple sclerosis: a Latin American experts meeting,” Multiple Sclerosis, vol. 15, no. 3, pp. S1–S12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. P. O'Connor and V. Devonshire, “The use of disease-modifying agents in multiple sclerosis—by the Canadian network of MS clinics,” Canadian Journal of Neurological Sciences, vol. 35, no. 2, pp. 127–132, 2008. View at Google Scholar · View at Scopus
  92. D. Karussis, L. D. Biermann, S. Bohlega et al., “A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting,” European Journal of Neurology, vol. 13, no. 1, pp. 61–71, 2006. View at Publisher · View at Google Scholar
  93. National Multiple Sclerosis Society USA (NMSS), “Disease management consensus statement [online],” October 2010, http://www.nmss.org/.
  94. T. Kuhlmann, G. Lingfeld, A. Bitsch, J. Schuchardt, and W. Brück, “Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time,” Brain, vol. 125, no. 10, pp. 2202–2212, 2002. View at Google Scholar · View at Scopus
  95. N. De Stefano, S. Narayanan, G. S. Francis et al., “Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability,” Archives of Neurology, vol. 58, no. 1, pp. 65–70, 2001. View at Google Scholar · View at Scopus
  96. M. Filippi, M. Rovaris, M. Inglese et al., “Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 364, no. 9444, pp. 1489–1496, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Paolillo, M. C. Piattella, P. Pantano et al., “The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA,” Journal of Neurology, vol. 251, no. 4, pp. 432–439, 2004. View at Publisher · View at Google Scholar
  98. B. Turner, X. Lin, G. Calmon, N. Roberts, and L. D. Blumhardt, “Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years,” Multiple Sclerosis, vol. 9, no. 1, pp. 21–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. P. A. Brex, O. Ciccarelli, J. I. O'Riordan, M. Sailer, A. J. Thompson, and D. H. Miller, “A longitudinal study of abnormalities on MRI and disability from multiple sclerosis,” The New England Journal of Medicine, vol. 346, no. 3, pp. 158–164, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Francis, “Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results,” Neurology, vol. 56, no. 11, pp. 1496–1504, 2001. View at Google Scholar
  101. L. D. Jacobs, R. W. Beck, J. H. Simon et al., “Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis,” The New England Journal of Medicine, vol. 343, no. 13, pp. 898–904, 2000. View at Publisher · View at Google Scholar
  102. G. Comi, M. Filippi, F. Barkhof et al., “Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study,” The Lancet, vol. 357, no. 9268, pp. 1576–1582, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. L. Kappos, C. H. Polman, M. S. Freedman et al., “Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes,” Neurology, vol. 67, no. 7, pp. 1242–1249, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. L. Kappos, M. S. Freedman, C. H. Polman et al., “Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study,” The Lancet, vol. 370, no. 9585, pp. 389–397, 2007. View at Publisher · View at Google Scholar
  105. G. Comi, V. Martinelli, M. Rodegher et al., “Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 374, no. 9700, pp. 1503–1511, 2009. View at Publisher · View at Google Scholar
  106. L. Kappos, C. Polman, C. Pozzilli, A. Thompson, and F. Dahlke, “Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis,” The Lancet, vol. 352, no. 9139, pp. 1491–1497, 1998. View at Publisher · View at Google Scholar
  107. G. Francis, “Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results,” Neurology, vol. 56, no. 11, pp. 1496–1504, 2001. View at Google Scholar
  108. J. A. Cohen, A. D. Goodman, F. R. Heidenreich et al., “Results of IMPACT, a phase 3 trial of interferon beta-1a in secondary progressive MS,” Neurology, vol. 56, supplement 3, pp. A148–A149, 2001. View at Google Scholar
  109. H. Panitch, “Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study,” Neurology, vol. 63, no. 10, pp. 1788–1795, 2004. View at Google Scholar
  110. A. N. Boyko, “Clinical effects and tolerability of high-dose, high-frequency recombinant interferon β-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence,” Expert Opinion on Biological Therapy, vol. 10, no. 4, pp. 653–666, 2010. View at Publisher · View at Google Scholar
  111. H. L. Tremlett and J. Oger, “Interrupted therapy: stopping and switching of the β-interferons prescribed for MS,” Neurology, vol. 61, no. 4, pp. 551–554, 2003. View at Google Scholar · View at Scopus
  112. V. Devonshire, Y. Lapierre, R. Macdonell et al., “The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis,” European Journal of Neurology, vol. 18, no. 1, pp. 69–77, 2011. View at Publisher · View at Google Scholar
  113. C. H. Polman, A. Bertolotto, F. Deisenhammer et al., “Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis,” The Lancet Neurology, vol. 9, no. 7, pp. 740–750, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Noronha, “Neutralizing antibodies to interferon,” Neurology, vol. 68, supplement 4, no. 24, pp. S16–S22, 2007. View at Publisher · View at Google Scholar
  115. A. P. Ross, “Tolerability, adherence, and patient outcomes,” Neurology, vol. 71, no. 24, pp. S21–23, 2008. View at Google Scholar · View at Scopus